The ongoing DESPIAD (Depletion of serum amyloid P component in Alzheimer’s disease), double-blind, placebo controlled, 1 year, phase 2b clinical trial of SAP depletion by miridesap in patients with Alzheimer’s disease, is monitoring cortical atrophy, cerebral amyloid burden, cognition and multiple other blood and CSF biomarkers including neurofilament light chain, aiming to detect any significant effects on disease progression (https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003284-19/GB). The gene discussed is NEFL; the disease is Cerebral cortical atrophy.